Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Pancreatic progress
February 2019
SHARING OPTIONS:

HOUSTON—In preliminary animal studies of WP1732, a lead drug of Moleculin Biotech Inc., the compound demonstrated enhanced activity in pancreatic cancer when combined with checkpoint blockade antibodies, the company announced in early January. Moleculin's drug candidates are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center. Walter Klemp, Moleculin’s chairman and CEO, noted that the results are “significant,” particularly when combined with data from studies of WP1066: “It shows that this is a consistent capability across our platform of STAT3 inhibitors, and it further supports independent research suggesting that STAT3 may be a key to enabling checkpoint blockade activity in otherwise resistant tumors. Importantly, though, when you couple this with our recent findings that WP1732 accumulates disproportionately in the pancreas, we believe it points to WP1732 as a potentially pivotal new approach to treating pancreatic cancer. Expansion of the WP1732 and WP1066 in-vivo studies is in progress.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.